Abiopharma

Axsome Therapeutics Initiates FOCUS-3 Phase 3 Trial of Solriamfetol in Adolescents with Attention Deficit Hyperactivity Disorder (ADHD)

Avalo Therapeutics to Join the Russell 2000® and Russell 3000® Indexes

Beyond Air® Reports Fourth Quarter and Full Year 2026 Financial Results and Provides Corporate Update

Baker Hughes Announces Dates for Second-Quarter Earnings Release and Webcast

Fury Announces Results of Annual General Meeting of Shareholders

Mandatory Cash Dividend/ Distribution:

General Announcement: Net Asset Value Per Unit

DAYBU® (trofinetide) Recommended for Approval in the European Union by CHMP

Net Asset Value(s)

BOSS Zhipins Ongoing Share Repurchases Reach Over RMB1.99 Billion in 2026